Sequencing of Biospecimen Samples to Advance Disease Research

CARLSBAD, Calif. & LUXEMBOURG–During an official visit of the Translational Genomics Research Institute (TGen) by H.R.H. Prince Guillaume, Hereditary Grand Duke of Luxembourg and Jeannot Krecké, Luxembourg’s Minister for the Economy & Foreign Trade, Life Technologies Corporation (NASDAQ:LIFE) and the Integrated Biobank of Luxembourg (IBBL) today announced a strategic partnership aimed at advancing the field of personalized medicine and yielding greater insights into the genetic causes of disease.

“By partnering with Life Technologies, IBBL is gaining access to cutting-edge sequencing technology, an important step to building an advanced technology infrastructure and a successful biomedical research industry in Luxembourg”

The Integrated Biobank of Luxembourg (IBBL) is an independent, non-profit biobanking and biotechnology foundation designed to support investigators worldwide in a new era of research and the next generation of healthcare. With an initial focus on cancer, the IBBL collects, stores, analyzes, and distributes a wide variety of the highest quality biospecimen samples while ensuring the strictest confidentiality and protection of donors’ data. The IBBL has the technology and expertise to provide valuable genetic and molecular information in addition to medical records and environmental factors related to the donor.

The IBBL will use Life Technologies’ Applied Biosystems SOLiD™ System, the most accurate next generation sequencing platform available today, to sequence its wide range of samples. This work could result in greater understanding of the genetic basis for many diseases, and could have application in various areas such as disease based research and, in the future, sequencing for clinical diagnosis.

“We’re pleased to become the sequencing technology partner to IBBL,” said Mark Stevenson, President and Chief Operating Officer for Life Technologies. “Our SOLiD system is the perfect technology to be used for sequencing IBBL’s well characterized samples, and we look forward to working with them to advance their goal of being a leader in the advancement of personalized medicine.”

“By partnering with Life Technologies, IBBL is gaining access to cutting-edge sequencing technology, an important step to building an advanced technology infrastructure and a successful biomedical research industry in Luxembourg,” said Dr. Jean-Claude Schmit, President of IBBL. “Working hand in hand with one of the leading companies in the field and contributing to new developments will allow IBBL to have early access to constantly evolving technologies and to offer the highest quality genetic data to our research collaborators.”

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

About IBBL (www.ibbl.lu)

The Integrated Biobank of Luxembourg – co-founded in 2008 by the nation’s three Public Research Centers, and the University, and developed in partnership with the Translational Genomics Research Institute (TGen) – is part of a major strategic effort initiated by the government of the Grand Duchy of Luxembourg to help the country develop cutting-edge skills and expertise in molecular medicine. IBBL aims to contribute directly to improved prevention, diagnosis and treatment of a range of diseases. While most European and U.S. biobanks focus on collection and distribution of specimens, the IBBL will focus in addition on sample processing and analysis and on technological advances in biobanking and biospecimen research. The IBBL will implement uniform standards for collection, storage and distribution of a full range of tissue samples, including blood, serum and tumor tissues and will provide molecular-based characterizations of biospecimens linked to clinical data. The project will leverage expertise in biology, pathology, genetics, proteomics, bioinformatics, and systems biology. The IBBL will serve as a centralized resource for sharing and comparing research results through a robust, scalable and secure bioinformatics system. For more information, visit www.ibbl.lu.

Life Technologies Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.